Haloperidol conditioned catalepsy in rats: A possible role for D 1-like receptors

International Journal of Neuropsychopharmacology

Volumn 15, Issue 10, 2012, Pages 1525-1534

  Banasikowski, Tomek J ^a   Beninger, Richard J ^a,b,c  

^a QUEEN S UNIVERSITY   (Canada)

^b Department Psychology ^*  (Canada)

^c QUEEN S UNIVERSITY   (Canada)

Author keywords

Catalepsy; context dependency; sensitization

Indexed keywords

DOPAMINE 1 RECEPTOR; DOPAMINE 2 RECEPTOR; DOPAMINE 2 RECEPTOR BLOCKING AGENT; HALOPERIDOL; SCH 23990; SODIUM CHLORIDE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BEHAVIOR; CATALEPSY; CONTROLLED STUDY; DRUG EFFECT; HYPOTHESIS; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; SENSITIZATION;

ANIMALS; CATALEPSY; CONDITIONING (PSYCHOLOGY); DOPAMINE ANTAGONISTS; DOSE-RESPONSE RELATIONSHIP, DRUG; HALOPERIDOL; MALE; RATS; RATS, WISTAR; REACTION TIME; RECEPTORS, DOPAMINE D1;

EID: 84867278901     PISSN: 14611457     EISSN: 14695111     Source Type: Journal    
DOI: 10.1017/S1461145711001696     Document Type: Article

References (79)

1. Agid O, Kapur S, Arenovich T, Zipursky RB (2003). Delayed-onset hypothesis of antipsychotic action : a hypothesis tested and rejected. Archives of General Psychiatry 60, 1228-1235.
2. Alttoa A, Eller M, Herm L, Rinken A, Harro J (2007). Amphetamine-induced locomotion, behavioral sensitization to amphetamine, and striatal D2 receptor function in rats with high or low spontaneous exploratory activity : differences in the role of locus coeruleus. Brain Research 1131, 138-148.
3. Amtage J, Schmidt WJ (2003). Context-dependent catalepsy intensification is due to classical conditioning and sensitization. Behavioural Pharmacology 14, 563-567.
4. Ayuso-Gutierrez JL, del Rio Vega JM (1997). Factors influencing relapse in the long-term course of schizophrenia. Schizophrenia Research 28, 199-206.
5. Baik JH, Picetti R, Saiardi A, Thiriet G, et al. (1995). Parkinsonian-like locomotor impairment in mice lacking dopamine D2 receptors. Nature 377, 424-428.
6. Banasikowski TJ, Beninger RJ (2010). Conditioned drug effects. In : Stolerman IP (Ed.) Encyclopedia of Psychopharmacology (pp. 325-331). Heidelberg: Springer.
7. Barnes DE, Robinson B, Csernansky JG, Bellows EP (1990). Sensitization vs. tolerance to haloperidol-induced catalepsy : multiple determinants. Pharmacology Biochemistry and Behaviour 36, 883-887.
8. Beninger RJ (1988). The slow therapeutic action of antipsychotic drugs: a possible mechanism involving the role of dopamine in incentive learning. In : Simon P, Soubrié P, Wildlocher D (Eds.), Animal Models of Psychiatric Disorders Vol. 1 : Selected Models of Anxiety, Depression and Psychosis (pp. 36-51). Basel : Karger.
9. Berendse HW, Groenewegen HJ, Lohman AH (1992). Compartmental distribution of ventral striatal neurons projecting to the mesencephalon in the rat. Journal of Neuroscience 12, 2079-2103.
10. Bunney BS, Grace AA (1978). Acute and chronic haloperidol treatment : comparison of effects on nigral dopaminergic cell activity. Life Science 23, 1715-1727.
11. Cador M, Bjijou Y, Cailhol S, Stinus L (1999). D-amphetamine-induced behavioral sensitization : implication of a glutamatergic medial prefrontal cortex-ventral tegmental area innervation. Neuroscience 94, 705-721.
12. Calabresi P, Centonze D, Gubellini P, Pisani A, et al. (2000). Acetylcholine-mediated modulation of striatal function. Trends in Neuroscience 23, 120-126.
13. Centonze D, Usiello A, Costa C, Picconi B, et al. (2004). Chronic haloperidol promotes corticostriatal long-term potentiation by targeting dopamine D2L receptors. Journal of Neuroscience 24, 8214-8222.
14. Cervo L, Samanin R (1995). Effects of dopaminergic and glutamatergic receptor antagonists on the acquisition and expression of cocaine conditioning place preference. Brain Research 673, 242-250.
15. Chiodo LA, Bunney BS (1983). Typical and atypical neuroleptics : differential effects of chronic administration on the activity of A9 and A10 midbrain dopaminergic neurons. Journal of Neuroscience 3, 1607-1619.
16. Choi WY, Balsam PD, Horvitz JC (2005). Extended habit training reduces dopamine mediation of appetitive response expression. Journal of Neuroscience 25, 6729-6733.
17. Costall B, Naylor RJ (1974). On catalepsy and catatonia and the predictability of the catalepsy test for neuroleptic activity. Psychopharmacologia 34, 233-241.
18. Costall B, Naylor RJ, Olley JE (1972). On the involvement of the caudate-putamen, globus pallidus and substantia nigra with neuroleptic and cholinergic modification of locomotor activity. Neuropharmacology 11, 317-330.
19. Costall B, Olley JE (1971). Cholinergic and neuroleptic induced catalepsy : modification by lesions in the globus pallidus and substantia nigra. Neuropharmacology 10, 581-594.
20. Crocker AD, Hemsley KM (2001). An animal model of extrapyramidal side effects induced by antipsychotic drugs: relationship with D2 dopamine receptor occupancy. Progress in Neuropsychopharmacology and Biological Psychiatry 25, 573-590.
21. Dalley JW, Laane K, Theobald DE, Armstrong HC, et al. (2005). Time-limited modulation of appetitive Pavlovian memory by D1 and NMDA receptors in the nucleus accumbens. Proceedings of the National Academy of Sciences USA 102, 6189-6194.
22. de Sousa Moreira LF, da Conceição Camargo Pinheiro M, Masur J (1982). Catatonic behavior induced by haloperidol, increased by retesting and elicited without drug in rats. Pharmacology 25, 1.
23. Dijk S, Krugers HJ, Korf J (1991). The effect of theophylline and immobilization stress on haloperidol-induced catalepsy and on metabolism in the striatum and hippocampus, studied with lactography. Neuropharmacology 30, 469-473.
24. El-Ghundi MB, Fan T, Karasinska JM, Yeung J, et al. (2010). Restoration of amphetamine-induced locomotor sensitization in dopamine D1 receptor-deficient mice. Psychopharmacology (Berlin) 207, 599-618.
25. Elliott PJ, Close SP, Walsh DM, Hayes AG, et al. (1990). Neuroleptic-induced catalepsy as a model of Parkinson's disease. I. Effect of dopaminergic agents. Journal of Neural Transmission Parkinson's Disease and Dementia Section 2, 79-89.
26. Fallon P, Dursun SM (2010). A naturalistic controlled study of relapsing schizophrenic patients with tardive dyskinesia and supersensitivity psychosis. Journal of Psychopharmacology, 25, 755-762.
27. Gaebel W, Pietzcker A (1985). Multidimensional study of the outcome of schizophrenic patients 1 year after clinic discharge. Predictors and influence of neuroleptic treatment. European Archive in Psychiatry and Neurological Sciences 235, 45-52.
28. Gerfen CR, Young WS (1988). Distribution of striatonigral and striatopallidal peptidergic neurons in both patch and matrix compartments : an in situ hybridization histochemistry and fluorescent retrograde tracing study. Brain Research 460, 161-167.
29. Grace AA, Bunney BS, Moore H, Todd CL (1997). Dopamine-cell depolarization block as a model for the therapeutic actions of antipsychotic drugs. Trends in Neuroscience 20, 31-37.
30. Gruen RJ, Deutch AY, Roth RH (1990). Perinatal diazepam exposure: alterations in exploratory behavior and mesolimbic dopamine turnover. Pharmacology Biochemistry and Behavior 36, 169-175.
31. Hinson RE, Poulos CX, Thomas WL (1982). Learning in tolerance to haloperidol-induced catalepsy. Progress in Neuropsychopharmacology and Biological Psychiatry 6, 395-398.
32. Hornykiewicz O (1973). Parkinson's disease : from brain homogenate to treatment. Federation Proceedings 32, 183-190.
33. Klein A, Schmidt WJ (2003). Catalepsy intensifies context-dependently irrespective of whether it is induced by intermittent or chronic dopamine deficiency. Behavioural Pharmacology 14, 49-53.
34. Klemm WR (1983). Cholinergic-dopaminergic interactions in experimental catalepsy. Psychopharmacology (Berlin) 81, 24-27.
35. Klemm WR (1985a). Evidence for a cholinergic role in haloperidol-induced catalepsy. Psychopharmacology (Berlin) 85, 139-142.
36. Klemm WR (1985b). Neuroleptic-induced catalepsy : a D2 blockade phenomenon? Pharmacology Biochemistry and Behaviour 23, 911-915.
37. Klemm WR (1993). The catalepsy of blocked dopaminergic receptors. Psychopharmacology (Berlin) 111, 251-255.
38. Klemm WR, Block H (1988). D-1 and D-2 receptor blockade have additive cataleptic effects in mice, but receptor effects may interact in opposite ways. Pharmacology Biochemistry and Behaviour 29, 223-229.
39. Klockgether T, Schwarz M, Turski L, Sontag KH (1988). Catalepsy after microinjection of haloperidol into the rat medial prefrontal cortex. Experimental Brain Research 70, 445-447.
40. Lanis A, Schmidt WJ (2001). NMDA receptor antagonists do not block the development of sensitization of catalepsy, but make its expression state-dependent. Behavioural Pharmacology 12, 143-149.
41. Lappalainen J, Hietala J, Syvalahti E (1989). Differential tolerance to cataleptic effects of SCH 23390 and haloperidol after repeated administration. Psychopharmacology (Berlin) 98, 472-475.
42. Lidsky TI, Banerjee SP (1993). Acute administration of haloperidol enhances dopaminergic transmission. Journal of Pharmacology and Experimental Therapeutics 265, 1193-1198.
43. Lipska BK, Jaskiw GE, Braun AR, Weinberger DR (1995). Prefrontal cortical and hippocampal modulation of haloperidol-induced catalepsy and apomorphine-induced stereotypic behaviors in the rat. Biological Psychiatry 38, 255-262.
44. Lodge DJ, Grace AA (2008). Amphetamine activation of hippocampal drive of mesolimbic dopamine neurons: a mechanism of behavioral sensitization. Journal of Neuroscience 28, 7876-7882.
45. Mazurski EJ, Beninger RJ (1991). Effects of selective drugs for dopaminergic D1 and D2 receptors on conditioned locomotion in rats. Psychopharmacology (Berlin) 105, 107-112.
46. Meller E, Kuga S, Friedhoff AJ, Goldstein M (1985). Selective D2 dopamine receptor agonists prevent catalepsy induced by SCH 23390, a selective D1 antagonist. Life Science 36, 1857-1864.
47. Miller R (2009). Mechanisms of action of antipsychotic drugs of different classes, refractoriness to therapeutic effects of classical neuroleptics, and individual variation in sensitivity to their actions : Part I. Current Neuropharmacology 7, 302-314.
48. Miller R, Wickens JR, Beninger RJ (1990). Dopamine D-1 and D-2 receptors in relation to reward and performance : a case for the D-1 receptor as a primary site of therapeutic action of neuroleptic drugs. Progress in Neurobiology 34, 143-183.
49. Morelli M, di Chiara G (1985). Catalepsy induced by SCH 23390 in rats. European Journal of Pharmacology 117, 179-185.
50. Ogren SO, Fuxe K (1988). D1-and D2-receptor antagonists induce catalepsy via different efferent striatal pathways. Neuroscience Letters 85, 333-338.
51. Ossowska K, Karcz M, Wardas J, Wolfarth S (1990). Striatal and nucleus accumbens D1/D2 dopamine receptors in neuroleptic catalepsy. European Journal of Pharmacology 182, 327-334.
52. Papeschi R (1972). Dopamine, extrapyramidal system, and psychomotor function. Psychiatra Neurologia Neurochirurgia 75, 13-48.
53. Parashos SA, Marin C, Chase TN (1989). Synergy between a selective D1 antagonist and a selective D2 antagonist in the induction of catalepsy. Neuroscience Letters 105, 169-173.
54. Poulos CX, Hinson R (1982). Pavlovian conditional tolerance to haloperidol catalepsy : evidence of dynamic adaptation in the dopaminergic system. Science 218, 491-492.
55. Redgrave P, Gurney K (2006). The short-latency dopamine signal : a role in discovering novel actions? Nature Reviews Neuroscience 7, 967-975.
56. Reynolds JN, Wickens JR (2000). Substantia nigra dopamine regulates synaptic plasticity and membrane potential fluctuations in the rat neostriatum, in vivo. Neuroscience 99, 199-203.
57. Reynolds JN, Wickens JR (2002). Dopamine-dependent plasticity of corticostriatal synapses. Neural Networks 15, 507-521.
58. Salamone JD, Correa M (2002). Motivational views of reinforcement: implications for understanding the behavioral functions of nucleus accumbens dopamine. Behavioural Brain Research 137, 3-25.
59. Sanberg PR, Bunsey MD, Giordano M, Norman AB (1988). The catalepsy test : its ups and downs. Behavioural Neuroscience 102, 748-759.
60. Sanberg PR, Pisa M, Faulks IJ, Fibiger HC (1980). Experimental influences on catalepsy. Psychopharmacology (Berlin) 69, 225-226.
61. Shen W, Flajolet M, Greengard P, Surmeier DJ (2008). Dichotomous dopaminergic control of striatal synaptic plasticity. Science 321, 848-851.
62. Schmidt WJ, Beninger RJ (2006). Behavioural sensitization in addiction, schizophrenia, Parkinson's disease and dyskinesia. Neurotoxicity Research 10, 161-166.
63. Schmidt WJ, Tzschentke TM, Kretschmer BD (1999). State-dependent blockade of haloperidol-induced sensitization of catalepsy by MK-801. European Journal of Neuroscience 11, 3365-3368.
64. Smith-Roe SL, Kelley AE (2000). Coincident activation of NMDA and dopamine D1 receptors within the nucleus accumbens core is required for appetitive instrumental learning. Journal of Neuroscience 20, 7737-7742.
65. Srinivasan J, Schmidt WJ (2004). Intensification of cataleptic response in 6-hydroxydopamine-induced neurodegeneration of substantia nigra is not dependent on the degree of dopamine depletion. Synapse 51, 213-218.
66. Stern ER, Horvitz JC, Cote LJ, Mangels JA (2005). Maintenance of response readiness in patients with Parkinson's disease : evidence from a simple reaction time task. Neuropsychology 19, 54-65.
67. Surmeier DJ, Ding J, Day M, Wang Z, et al. (2007). D1 and D2 dopamine-receptor modulation of striatal glutamatergic signaling in striatal medium spiny neurons. Trends in Neuroscience 30, 228-235.
68. Tozzi A, de Iure A, di Filippo M, Tantucci M, et al. (2011). The distinct role of medium spiny neurons and cholinergic interneurons in the D/AA receptor interaction in the striatum : implications for Parkinson's disease. Journal of Neuroscience 31, 1850-1862.
69. Tucci S, Fernandez R, Baptista T, Murzi E, et al. (1994). Dopamine increase in the prefrontal cortex correlates with reversal of haloperidol-induced catalepsy in rats. Brain Research Bulletin 35, 125-133.
70. Undie AS, Friedman E (1988). Differences in the cataleptogenic actions of SCH23390 and selected classical neuroleptics. Psychopharmacology (Berlin) 96, 311-316.
71. Usiello A, Baik JH, Rouge-Pont F, Picetti R, et al. (2000). Distinct functions of the two isoforms of dopamine D2 receptors. Nature 408, 199-203.
72. Valenti O, Cifelli P, Gill KM, Grace AA (2011). Antipsychotic drugs rapidly induce dopamine neuron depolarization block in a developmental rat model of schizophrenia. Journal of Neuroscience 31, 12330-12338.
73. Vezina P (1996). D1 dopamine receptor activation is necessary for the induction of sensitization by amphetamine in the ventral tegmental area. Journal of Neuroscience 16, 2411-2420.
74. Wang Z, Kai L, Day M, Ronesi J, et al. (2006). Dopaminergic control of corticostriatal long-term synaptic depression in medium spiny neurons is mediated by cholinergic interneurons. Neuron 50, 443-452.
75. Wadenberg ML, Kapur S, Soliman A, Jones C, et al. (2000). Dopamine D2 receptor occupancy predicts catalepsy and the suppression of conditioned avoidance response behavior in rats. Psychopharmacology (Berlin) 150, 422-429.
76. Wanibuchi F, Usuda S (1990). Synergistic effects between D-1 and D-2 dopamine antagonists on catalepsy in rats. Psychopharmacology (Berlin) 102, 339-342.
77. Wiecki TV, Riedinger K, von Ameln-Mayerhofer A, Schmidt WJ, et al. (2009). A neurocomputational account of catalepsy sensitization induced by D2 receptor blockade in rats : context dependency, extinction, and renewal. Psychopharmacology (Berlin) 204, 265-277.
78. Wise RA (2004). Dopamine, learning and motivation. Nature Reviews Neuroscience 5, 483-494.
79. Wolf ME, Dahlin SL, Hu XT, Xue CJ, et al. (1995). Effects of lesions of prefrontal cortex, amygdala, or fornix on behavioral sensitization to amphetamine : comparison with N-methyl-D-aspartate antagonists. Neuroscience 69, 417-439.